Rising Screening Programs Strengthen Demand for Gastric Cancer Diagnostics

0
3

Gastric Cancer Diagnostics Market size was valued at USD 1.43 billion in 2025 and is estimated at USD 1.53 billion in 2026. According to Polaris Market Research, it is projected to reach USD 2.78 billion by 2034, registering a CAGR of 7.70% from 2026 to 2034. Growth is largely driven by the rising prevalence of gastric cancer worldwide and a stronger focus on early disease detection through screening programs.

Rising Case Volumes Keep Demand Steady

The Gastric Cancer Diagnostics Market rests on a large and persistent patient pool. According to the World Cancer Research Fund and the Global Cancer Observatory, there were 968,784 new cases of stomach cancer globally in 2022, with Asian countries such as China and Japan accounting for a substantial portion. Volumes of this scale require a dependable diagnostic infrastructure, from initial screening tools to advanced confirmatory tests. The growing geriatric population adds further momentum, because gastric cancer incidence rises significantly with age, making older adults a high-risk group that needs more frequent screening.

Personalized Medicine and Technology Reshape Diagnosis

The shift toward personalized medicine is another important driver of the Gastric Cancer Diagnostics Market. Tailoring therapy depends on identifying cancer biomarkers, genetic mutations and the molecular profile of a patient’s tumor, which moves care away from a one-size-fits-all approach.

Technology is advancing in parallel. Narrowband imaging, liquid biopsy, next-generation sequencing and breath tests are making detection more accurate and less invasive. Artificial intelligence is also gaining ground: it sharpens the analysis of endoscopic images and pathology slides, helps detect early-stage signs of stomach cancer, and shortens the time needed to interpret diagnostic data. Digital pathology, companion diagnostics and faster molecular testing further improve laboratory efficiency and speed up treatment decisions.

Segment Highlights

By product, reagents and consumables held the largest share of 64.2% in 2025, driven by consistent, high-volume use across nearly every diagnostic procedure. Antibodies, stains and assay kits are needed for each biopsy and for detecting biomarkers such as HER2 and PD-L1. Instruments are expected to record the fastest growth, at a CAGR of 10.4%, as advanced endoscopes and molecular platforms are adopted.

By disease type, adenocarcinoma accounted for 68.6% of the Gastric Cancer Diagnostics Market in 2025, as it is the most prevalent form of stomach cancer. Gastric lymphoma, though less common, is projected to grow fastest, supported by better diagnostic accuracy and growing recognition of MALT lymphoma linked to H. pylori infection.

By end use, hospitals led in 2025 because they house the endoscopy suites, imaging departments and pathology labs central to diagnosis. Diagnostic laboratories are anticipated to grow fastest, as molecular diagnostics, liquid biopsy and sequencing are typically processed in specialized labs.

Explore The Complete Comprehensive Report Here : https://www.polarismarketresearch.com/industry-analysis/gastric-cancer-diagnostics-market

Regional Outlook

North America led the Gastric Cancer Diagnostics Market with a 42.5% share in 2025, supported by advanced healthcare infrastructure, high awareness of early diagnosis, strong research investment and favorable reimbursement. In the U.S., the National Institutes of Health awarded a significant grant in April 2025 to evaluate the feasibility of gastric cancer screening, underscoring the commitment to earlier detection.

Europe is benefiting from an aging population and efforts to implement organized population-based screening in higher-incidence areas, while Germany integrates comprehensive pathology and biomarker testing into patient management.

Asia Pacific is projected to expand at a 9.7% CAGR, the fastest among regions, owing to the highest global incidence of gastric cancer. Japan, in particular, is known for widespread screening and routine endoscopic examinations, which have contributed to higher rates of early diagnosis.

Competitive Landscape and Recent Developments

The industry blends established healthcare companies with innovative biotechnology firms. Prominent participants include F. Hoffmann-La Roche Ltd., Abbott Laboratories, QIAGEN, Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Illumina, Inc., Myriad Genetics, Inc., Mirxes Pte. Ltd., Vela Diagnostics, BIOMÉRIEUX and AI Medical Service Inc. Competition centers on technological innovation, diagnostic accuracy, speed of results and seamless integration into clinical workflows.

Recent activity points to a companion diagnostics focus. In July 2026, Agilent Technologies announced U.S. FDA approval for its PD-L1 IHC 28-8 pharmDx assay as a companion diagnostic for gastric, gastroesophageal junction and esophageal cancers. In October 2024, Roche introduced the VENTANA CLDN18 (43-14A) RxDx Assay, the first immunohistochemistry-based companion diagnostic with CE Mark approval for identifying CLDN18 expression in gastric or GEJ adenocarcinoma. In May 2025, SSI Diagnostica Group announced its acquisition of Gulf Coast Scientific to strengthen its gastrointestinal testing portfolio.

Cost and Adoption

Molecular and genetic tests remain relatively costly compared with conventional methods, but automation and reusable tools improve long-term efficiency. Insurance coverage, government screening programs and better healthcare infrastructure are widening access, and costs are expected to fall gradually as technology matures.

Gastric Cancer Diagnostics Market growth will continue to be shaped by early diagnosis, biomarker discovery, AI-assisted analysis and digital pathology. With a forecast value of USD 2.78 billion by 2034, the industry is moving toward faster, less invasive and more personalized diagnostics, giving manufacturers, laboratories and healthcare providers a clear opportunity to support better patient outcomes.

More Trending Latest Reports By Polaris Market Research:

Mining Equipment Market

Prebiotic Ingredient Market

Modular Containers Market

Caprolactam Market

Prebiotic Ingredient Market

Human Microbiome Therapeutics Market

3 in 1 Electric Drive Module (eDrive Modules) Market

3D Motion Capture System Market

Benign Prostatic Hyperplasia Surgical Treatment Market

Zoeken
Categorieën
Read More
Health
Is Dark Circle Under Eye Treatment in Dubai Worth It?
Dark circles under the eyes are a common aesthetic concern that can make the face appear tired,...
By altadermaclinic 2026-07-18 06:58:40 0 678
Sports
Why Today’s Betting Users Look for Speed, Simplicity and Easy Navigation
I work as a digital product consultant, helping online businesses understand how real people...
By jones578 2026-08-12 01:20:25 0 656
Other
Electrical Safety Products Market Boosted by Demand for High-Voltage Safety Equipment: Forecast 2025 - 2035
Electrical Safety Products Market Overview: The global electrical safety products...
By prakash045 2026-08-04 06:18:39 0 378
Other
Sterile Injectable Contract Manufacturing Market Growth Driven by Outsourcing Trends
Polaris Market Research presents its latest market research report, titled “Sterile...
By pratap11 2026-09-18 10:53:00 0 322
Health
Venus Legacy vs Radiofrequency Skin Tightening Treatments
Venus Legacy is often categorized as a radiofrequency (RF) skin tightening...
By mominsaudi321 2026-11-10 06:41:29 0 107
AC Mingle https://acmingle.com